Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure

Nongnuch Sirachainan; Anannit Visudtibhan; Lojana Tuntiyatorn; Samart Pakakasama; Ampaiwan Chuansumrit; Suradej Hongeng

doi:10.1002/pbc.20848

Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure

Nongnuch Sirachainan
, Anannit Visudtibhan
, Lojana Tuntiyatorn
, Samart Pakakasama
, Ampaiwan Chuansumrit
, Suradej Hongeng

Department of Pediatrics

Ramathibodi Hospital

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

A 3-year-old male, diagnosed with stage 4 neuroblastoma, developed recurrent leptomeningeal metastasis after multi-modality treatment including multi-agent chemotherapy, surgery, high dose chemotherapy plus stem ceil rescue, cis-retinoic acid and intravenous (IV) topotecan. He then received intraommaya (IO) topotecan three times weekly (maximum dose; 0.4 mg). A complete response was achieved by a resolution of malignant cells in cerebrospinal fluid and resolution leptomeningeal enhancement by brain MRI. Treatment toxicities included low-grade fever and minimal headache. The duration of treatment response from IO topotecan was 18 weeks. The survival time from CNS recurrence in this patient was 13 months. We suggest IO topotecan be considered for neoplastic meningitis of tumors with known sensitivity to topotecan.

Original language	English
Pages (from-to)	169-172
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	50
Issue number	1
DOIs	https://doi.org/10.1002/pbc.20848
Publication status	Published - Jan 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Intraommaya
Leptomeningeal
Neuroblastoma
Topotecan

Access to Document

10.1002/pbc.20848

Cite this

@article{0cdfdc1839fb4420b2c60cd27d24d9e5,

title = "Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure",

abstract = "A 3-year-old male, diagnosed with stage 4 neuroblastoma, developed recurrent leptomeningeal metastasis after multi-modality treatment including multi-agent chemotherapy, surgery, high dose chemotherapy plus stem ceil rescue, cis-retinoic acid and intravenous (IV) topotecan. He then received intraommaya (IO) topotecan three times weekly (maximum dose; 0.4 mg). A complete response was achieved by a resolution of malignant cells in cerebrospinal fluid and resolution leptomeningeal enhancement by brain MRI. Treatment toxicities included low-grade fever and minimal headache. The duration of treatment response from IO topotecan was 18 weeks. The survival time from CNS recurrence in this patient was 13 months. We suggest IO topotecan be considered for neoplastic meningitis of tumors with known sensitivity to topotecan.",

keywords = "Intraommaya, Leptomeningeal, Neuroblastoma, Topotecan",

author = "Nongnuch Sirachainan and Anannit Visudtibhan and Lojana Tuntiyatorn and Samart Pakakasama and Ampaiwan Chuansumrit and Suradej Hongeng",

year = "2008",

month = jan,

doi = "10.1002/pbc.20848",

language = "English",

volume = "50",

pages = "169--172",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure

AU - Sirachainan, Nongnuch

AU - Visudtibhan, Anannit

AU - Tuntiyatorn, Lojana

AU - Pakakasama, Samart

AU - Chuansumrit, Ampaiwan

AU - Hongeng, Suradej

PY - 2008/1

Y1 - 2008/1

N2 - A 3-year-old male, diagnosed with stage 4 neuroblastoma, developed recurrent leptomeningeal metastasis after multi-modality treatment including multi-agent chemotherapy, surgery, high dose chemotherapy plus stem ceil rescue, cis-retinoic acid and intravenous (IV) topotecan. He then received intraommaya (IO) topotecan three times weekly (maximum dose; 0.4 mg). A complete response was achieved by a resolution of malignant cells in cerebrospinal fluid and resolution leptomeningeal enhancement by brain MRI. Treatment toxicities included low-grade fever and minimal headache. The duration of treatment response from IO topotecan was 18 weeks. The survival time from CNS recurrence in this patient was 13 months. We suggest IO topotecan be considered for neoplastic meningitis of tumors with known sensitivity to topotecan.

AB - A 3-year-old male, diagnosed with stage 4 neuroblastoma, developed recurrent leptomeningeal metastasis after multi-modality treatment including multi-agent chemotherapy, surgery, high dose chemotherapy plus stem ceil rescue, cis-retinoic acid and intravenous (IV) topotecan. He then received intraommaya (IO) topotecan three times weekly (maximum dose; 0.4 mg). A complete response was achieved by a resolution of malignant cells in cerebrospinal fluid and resolution leptomeningeal enhancement by brain MRI. Treatment toxicities included low-grade fever and minimal headache. The duration of treatment response from IO topotecan was 18 weeks. The survival time from CNS recurrence in this patient was 13 months. We suggest IO topotecan be considered for neoplastic meningitis of tumors with known sensitivity to topotecan.

KW - Intraommaya

KW - Leptomeningeal

KW - Neuroblastoma

KW - Topotecan

UR - https://www.scopus.com/pages/publications/36849024880

U2 - 10.1002/pbc.20848

DO - 10.1002/pbc.20848

M3 - Article

C2 - 16572404

AN - SCOPUS:36849024880

SN - 1545-5009

VL - 50

SP - 169

EP - 172

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 1

ER -

Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this